Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

NEJM

June 26, 2023

Enlaces

https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

Artículos Relacionadas

Management and follow-up strategies for patients with head and neck paraganglioma

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

✍🏻⚠️ Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes

Causes, prevention, and management of diabetes-related foot ulcers

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

Magnesium Disorders

Magnesium Disorders

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, pha

Highlights in the clinical nutrition literature: A critical appraisal of current research

Agenda

Noviembre 2024

Lun	Mar	Mié	Jue	Vie	Sáb	Dom
28	29	30	31	1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	1

Top